Latanoprost Actavis (Latanoprost)

Latanoprost is a prostaglandin analog used to manage conditions that involve elevated intra‑ocular pressure.

• Open‑angle glaucoma: reduces intra‑ocular pressure to slow disease progression.
• Ocular hypertension: lowers eye pressure to prevent development of glaucoma.
• Secondary open‑angle glaucoma: helps control pressure when caused by other ocular conditions.

• Latanoprost binds to prostaglandin F‑type receptors (FP receptors) in the ciliary muscle and scleral tissue, activating a cascade that remodels extracellular matrix and enhances uveoscleral outflow of aqueous humor. The increased outflow reduces intra‑ocular pressure, providing therapeutic benefit in glaucoma and ocular hypertension. This effect is dose‑dependent and persists with once‑daily administration, offering sustained pressure control without systemic absorption. The drug’s high ocular bioavailability is achieved through its lipophilic ester form, which is hydrolyzed to the active acid after penetration.

Latanoprost may cause ocular and systemic reactions; most are mild and reversible.

Common Side Effects

• Eye redness: transient hyperemia of the conjunctiva.
• Eye irritation: burning or stinging sensation after instillation.
• Increased eyelash growth: longer, thicker lashes.
• Darkening of iris: gradual increase in brown pigmentation.
• Blurred vision: temporary focusing changes.
• Foreign body sensation: feeling of grit in the eye.

Serious or Rare Side Effects

• Severe eye inflammation: uveitis or iritis requiring medical attention.
• Allergic reaction: swelling, itching, or rash around the eye.
• Vision loss: sudden decrease in visual acuity.
• Ocular infection: bacterial or fungal infection at the application site.
• Systemic hypotension: rare drop in blood pressure.

When prescribing Latanoprost, clinicians should consider several safety measures to minimize risks.

• Assess baseline intra‑ocular pressure: ensure appropriate indication before initiating therapy.
• Monitor iris color changes: inform patients that permanent darkening may occur.
• Avoid use in active ocular infection: postpone treatment until infection resolves.
• Caution in patients with asthma: prostaglandin analogs can rarely trigger bronchospasm.
• Discontinue if severe ocular inflammation develops: seek ophthalmologic evaluation.
• Store at ambient temperature: keep in original container, protect from light and moisture.

Latanoprost can interact with other ocular or systemic agents, affecting efficacy or safety.

Major Interactions (Avoid)

• Concurrent use of other intra‑ocular pressure‑lowering eye drops (e.g., timolol, dorzolamide): may cause excessive pressure reduction.
• Systemic non‑steroidal anti‑inflammatory drugs (NSAIDs): can diminish prostaglandin‑mediated outflow enhancement.

Moderate Interactions (Monitor Closely)

• Topical corticosteroids: may counteract IOP‑lowering effect.
• Anticholinergic eye drops: may affect pupil size and drug distribution.
• Contact lens wear: may reduce drug absorption; advise removal before instillation.
• Beta‑blocker eye drops: monitor for additive hypotensive effect.